Selective enhancement of cytarabine toxicity to AML blasts by differentiating agents.

e18063 Background: Cytarabine (AraC) is one of the mainstays of AML therapy, but, like other DNA damaging therapeutic agents it is rarely curative. Even high dose AraC regimens cannot in general be...